Key Highlights

  • Revenue up 24% to about £47.5m; Gross Profit up 27% to roughly £20.8m.
  • Net Debt cut 39% to around £5.1m on £7.5m operating cash flow.
  • Portfolio simplified via exit from infusion to focus on neonatal.
  • Multi-year US purchasing agreement secured through the Airon division.

The Latest Catalyst

Inspiration Healthcare (LSE:IHC)'s full-year results for the year to 31 January 2026, published in June 2026, showed a Business that has both grown strongly and sharpened its strategic focus. The AIM-listed medical-technology group reported Revenue up 24% and used the results to confirm its pivot towards neonatal intensive care, agreeing to transfer its infusion business to Micrel and doubling down on the higher-margin SLE ventilation franchise.

The catalyst is the combination of growth and self-help. Alongside the top-line jump, Inspiration delivered a large reduction in net debt and strong operating cash generation, addressing the balance-sheet concerns that had weighed on the shares through a turbulent couple of years. Management framed the year as the point at which the neonatal strategy began to translate into cash and profitability, rather than remaining a promise about future potential.

What the Numbers Show

Revenue reached about £47.5m, a 24% increase, with gross profit up 27% to roughly £20.8m as mix improved. Adjusted EBITDA came in at around £2.8m and Operating Cash Flow was strong at about £7.5m, helping cut net debt by 39% to approximately £5.1m. The company also reduced inventory by roughly a third, a meaningful working-capital improvement that flattered cash generation and de-risked the balance sheet.

The revenue quality bears scrutiny. Sales of the core SLE neonatal ventilation range grew 56%, but that figure was flattered by a one-off export contract worth about £9.5m; stripping that out, underlying SLE growth was around 10%. The group also secured a multi-year purchasing agreement with a major US healthcare provider through its Airon division, adding to recurring visibility. Management expressed confidence in meeting FY27 expectations, while flagging the transitional impact of exiting infusion — a reminder that the reported growth rate will be harder to repeat once the export contract annualises out.

The Bull Case

The bull case rests on focus and cash generation. By divesting infusion and concentrating on neonatal ventilation and monitoring, Inspiration is steering toward the parts of its portfolio with the strongest margins and clearest competitive position. The 27% rise in gross profit, ahead of revenue, is early evidence that the mix shift is working and that pricing power in specialist neonatal equipment is intact.

A 39% cut in net debt and £7.5m of operating cash flow transform the risk profile of a small-cap MedTech that previously carried a more stretched balance sheet. The multi-year US agreement through Airon and the international reach of the SLE Brand give the company a platform to expand in a structurally growing area — neonatal care Demand is underpinned by long-term clinical need and demographic factors rather than economic cycles. For a company of this size, a cleaner Balance Sheet also widens strategic options, from further product Investment to selective bolt-on deals.

Risks Investors Should Watch

The most important caveat is the quality of the growth. A large slice of the SLE increase came from a single £9.5m export contract that will not automatically repeat, so underlying growth of around 10% is the more relevant run-rate. Investors should watch whether the group can replace that one-off with recurring demand, because a step-down in reported revenue is a real possibility in the transition year.

Exiting infusion removes revenue in the near term, and management has been explicit about a transitional impact. As a small-cap medtech, Inspiration remains exposed to hospital procurement cycles, tender timing and currency, particularly given its growing US exposure and the associated dollar sensitivity. Adjusted EBITDA of £2.8m is still modest relative to revenue, so Margin progression from here is central to the Equity story; any slippage in cost control or gross margin would quickly undermine the improving narrative.

What Could Move the Shares Next?

Near-term catalysts include completion of the infusion transfer to Micrel and clarity on its financial impact, plus trading updates that show whether underlying SLE demand can sustain the momentum once the one-off export contract is annualised out. Progress on the US Airon agreement, new neonatal product launches and further net-debt reduction would all support the case.

The FY27 result will be the key test of whether the sharpened, neonatal-focused business can convert its stronger balance sheet into durable margin and cash growth. Any additional export or distribution contracts, or evidence of expanding US installed base, could act as positive surprises, while news of tender delays or pricing pressure in core markets would be the more obvious downside triggers for a stock of this scale.

Investor Takeaway

Inspiration Healthcare's results mark a genuine inflection for a small-cap medtech that has grown revenue, expanded margins and repaired its balance sheet in the same year. Bullish investors may focus on the 24% revenue rise, the 39% cut in net debt and the strategic clarity of concentrating on neonatal care. The key risk is that reported growth was boosted by a one-off £9.5m export contract, so the durability of underlying demand is unproven. The next results could provide evidence on whether roughly 10% underlying SLE growth can be sustained and margins can build from here. Investors will be watching the infusion exit and US expansion as the swing factors that will ultimately settle the valuation debate.